Share

    


Home / Search Results

Search Results

You searched for:

From January 24 to 28, 2022, ACCC co-sponsored Health Care Value Week—a series of virtual events supporting the advancement of value-based care.
In the absence of a successor to the Oncology Care Model (OCM), the future looks bleak.
As the United States healthcare system moves to value-based and bundled payments under alternative payment models, it is now more important than ever for cancer programs and practices to quantitatively and qualitatively measure to show the value that supportive cancer care services bring to patients.
Mercy Cancer Care responded to OP-35 was by developing an internal report that predicted the metrics for one of its larger oncology practices.
In my new role at ACCC as senior director, cancer care delivery and health policy, I am excited to take over writing this bimonthly column and communicating to our multidisciplinary membership about pertinent workforce, reimbursement, and cancer care delivery issues.
On Dec. 2, 2020, the Centers for Medicare & Medicaid Services (CMS) issued the final rules for the Hospital Outpatient Prospective Payment System (HOPPS or OPPS) for CY 2021.
To prevent implementation of the model, ACCC joined with the Global Colon Cancer Association, the National Infusion Center Association, and the Pharmaceutical Research and Manufacturers of America to file a lawsuit against the U.S. Department of Health and Human Services, seeking an immediate injunction to prevent the implementation of the MFN model.
On July 10, 2019, the Centers for Medicare & Medicaid Services (CMS) revealed new details of a proposed bundled payment model for radiation oncology services (“RO Model”).
At the ACCC 45th Annual Meeting and Cancer Center Business Summit, I announced my 2019-2020 President’s Theme: Collaborate. Educate. Compensate: A Prescription for Sustainable Care Delivery.
The February decision by the Center for Medicare and Medicaid Innovation (CMMI) to build its first specialty care model around oncology is an important indication of the agency’s focus on how to contain costs in cancer care.